BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
Globe Newswire•26/08/2026•07:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.